We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Effects of Caffeine in Tinnitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00628316
Recruitment Status : Completed
First Posted : March 5, 2008
Last Update Posted : March 22, 2011
Information provided by:
Faculdade de Medicina de Valenca

Brief Summary:
Caffeine intake is reported by many authors to enhance the perception of tinnitus. The aim of this study is to determine the effects of 1 month caffeine intake reduction in the scores of validated questionnaire Tinnitus Handicap Inventory (THI) and in a visual-analog scale (VAS).

Condition or disease Intervention/treatment Phase
Tinnitus Dietary Supplement: caffeine Not Applicable

Detailed Description:
A group of 50 patients who takes more than 3 small cups (50 ml) of caffeine daily and have tinnitus will be asked to reduce caffeine intake for 1 month. Scores of THI and VAS will be taken before and after this period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Caffeine Consumption on Tinnitus Perception
Study Start Date : January 2008
Actual Primary Completion Date : September 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Caffeine Tinnitus

Intervention Details:
  • Dietary Supplement: caffeine
    caffeine daily intake will be reduced form 150 ml per day

Primary Outcome Measures :
  1. Tinnitus Handicap Inventory [ Time Frame: 30 days ]

Secondary Outcome Measures :
  1. Visual Analog Scale [ Time Frame: 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • tinnitus for more than 6 months
  • THI > 38
  • no central acting drugs in the last 6 months
  • tympanogram type A-n
  • daily intake of caffeine greater than 150 ml

Exclusion Criteria:

  • vascular and muscular tinnitus
  • concomitant TMJ disorders
  • abnormal otoscopy
  • mixed and conductive hearing losses
  • Ménière disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00628316

Layout table for location information
Faculdade de Medicina de Valença
Valença, RJ, Brazil, 27600-000
OTOSUL Otorrinolaringologia Sul-Fluminense
Volta Redonda, RJ, Brazil, 27255-650
Sponsors and Collaborators
Faculdade de Medicina de Valenca
Layout table for investigator information
Study Chair: Ricardo R Figueiredo, MD,MSc Faculdade de Medicina de Valença
Layout table for additonal information
Responsible Party: Ricardo Rodrigues Figueiredo, MD, MSc, University of Valencia
ClinicalTrials.gov Identifier: NCT00628316    
Other Study ID Numbers: FMV 001 2008
First Posted: March 5, 2008    Key Record Dates
Last Update Posted: March 22, 2011
Last Verified: February 2008
Keywords provided by Faculdade de Medicina de Valenca:
Additional relevant MeSH terms:
Layout table for MeSH terms
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents